BRL-26830A

BRL-26830A is a β-adrenergic receptor agonist. BRL-26830A reduces body weight and increases metabolic rate in obese mouse models. BRL-26830A stimulates insulin release and significantly reduces blood glucose levels in ICR mouse models. BRL-26830A can be used to study endocrine and metabolic diseases such as obesity and diabetes[1][2][2].

87857-42-9

12352100

Adrenergic Receptor

GPCR/G Protein; Neuronal Signaling

Metabolism-sugar/lipid metabolism

Metabolic Disease

O=C(O)/C=C/C(O)=O.O=C(OC)C1=CC=C(C[C@@H](NC[C@@H](O)C2=CC=CC=C2)C)C=C1.[1/2]

C19H23NO3.1/2C4H4O4

371.45

[1]Connacher AA, et al. Clinical studies with the beta-adrenoceptor agonist BRL 26830A. Am J Clin Nutr. 1992 Jan;55 (1 Suppl) :258S-261S.|[2]Arch JR, et al. Thermogenic and antiobesity activity of a novel beta-adrenoceptor agonist (BRL 26830A) in mice and rats. Am J Clin Nutr. 1983 Oct;38 (4) :549-58. |[3]Yoshida T. The antidiabetic beta 3-adrenoceptor agonist BRL 26830A works by release of endogenous insulin. Am J Clin Nutr. 1992 Jan;55 (1 Suppl) :237S-241S. d

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-19002/

Reference compound1

No Development Reported